Equity · Healthcare
QDEL
NASDAQQuidelOrtho (QDEL)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 1.2B USD
- Revenue, year to Dec 2025
- 2.7B USD
- EPS, diluted, year to Dec 2025
- −16.69 USD
- 52-week range
- 9.95 USD – 35 USD
- Avg volume
- 386.7K
as of Jul 17, 2026
Have QuidelOrtho (QDEL) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no QuidelOrtho insider bought or sold shares on the open market; all 6 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 15 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Oct 2026 | Siegrist Jonathan PhilipEVP of R&D & CTO | Option exercise | 18,657 | |
| 15 Oct 2026 | Siegrist Jonathan PhilipEVP of R&D & CTO | Tax withheld | 6,695 | 93K USD |
| 15 Sep 2026 | Bowman Ronald LeeChief Human Resources Officer | Option exercise | 2,566 | |
| 15 Sep 2026 | Bowman Ronald LeeChief Human Resources Officer | Tax withheld | 921 | 10K USD |
| 15 Aug 2026 | Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting | Option exercise | 446 | |
| 15 Aug 2026 | Hanson Bryan MichaelEVP Global Port. Mgmt & Mkting | Tax withheld | 162 | 2K USD |
Which funds hold QuidelOrtho (QDEL)?
8 of the 45 institutional funds we track reported a QuidelOrtho position for the quarter ended 30 Jun 2026 — a combined 45.0M USD; the latest of those filings landed 14 Aug 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Added | 911,115 | 16.0M USD | +421.5% |
| Millennium Management | Added | 722,480 | 12.7M USD | +156.0% |
| D. E. Shaw & Co. | Held (±25%) | 270,233 | 4.7M USD | −1.6% |
| GAMCO Investors | Held (±25%) | 251,235 | 4.4M USD | −1.0% |
| Tudor Investment Corp | Held (±25%) | 194,953 | 3.4M USD | −16.9% |
| Marshall Wace | Added | 172,500 | 3.0M USD | +30.8% |
| Point72 Asset Management | Trimmed | 30,422 | 533K USD | −96.0% |
| Two Sigma Investments | New position | 17,402 | 305K USD |
Have members of Congress traded QuidelOrtho (QDEL)?
The most recent congressional trade disclosed in QuidelOrtho is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Jul 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 32 days |
What has been filed or recorded for QuidelOrtho (QDEL)?
The filings we hold for QuidelOrtho, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,189 shares | 15K USD notional · 0.002% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,783 shares | 19K USD notional · 0.003% of shares out |
| 27 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.78 USD | Revenue $619M |
| 27 Sep 2026 | Financials | Total assets | 5.8B USD | at period end |
| 27 Sep 2026 | Financials | Total equity | 1.8B USD | at period end |
| 28 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.36 USD | Revenue $631M |
| 29 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.35 USD | Revenue $620M |
| 28 Dec 2025 | Annual report | FY 2025 reported | EPS −16.69 USD | Revenue $2.73B |
| 28 Dec 2025 | Financials | Revenue | 2.7B USD | fiscal year |
| 28 Dec 2025 | Financials | Net income | −1.1B USD | fiscal year |
| 28 Dec 2025 | Financials | Diluted EPS | −16.69 USD | fiscal year |
| 28 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −10.78 USD | Revenue $700M |
| 29 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −3.77 USD | Revenue $614M |
| 30 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.19 USD | Revenue $693M |
| 29 Dec 2024 | Annual report | FY 2024 reported | EPS −30.54 USD | Revenue $2.78B |
What do people ask about QuidelOrtho (QDEL)?
What is QuidelOrtho’s market cap?1.2B
QuidelOrtho is worth 1.2B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is QuidelOrtho’s revenue?2.7B
QuidelOrtho reported revenue of 2.7B USD for the year ended 28 Dec 2025, as filed with the SEC. See Filings
Have QuidelOrtho insiders bought or sold shares recently?6 filings
In the 90 days to 10 Nov 2026, no QuidelOrtho insider bought or sold shares on the open market; all 6 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own QuidelOrtho?8 of 45
8 of the 45 funds we track reported a QuidelOrtho position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Millennium Management and D. E. Shaw & Co. See Funds
Have members of Congress traded QuidelOrtho?1 trade
Yes. 1 trade in QuidelOrtho appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 12 Jul 2023, filed 13 Aug 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did QuidelOrtho last report earnings?−0.78
QuidelOrtho last reported earnings on 27 Sep 2026 for Q3 2026, with EPS of −0.78 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 27 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings